If you missed this year’s Paris NASH meeting, you missed some exciting presentations featuring fresh, pivotal insights about Fatty Liver diseases and some new approaches to learning about this disease.
For this episode From the Vault, we take a look back at what has by far been the most downloaded episode in the history of the podcast: S2-E46 – Highlights from Paris NASH 2021. Jörn Schattenberg and Stephen Harrison combine to provide a robust synopsis of the meeting while Roger Green asks a few questions and keeps the discussion in-bounds:
10:20 – Jörn introduces Paris NASH and discusses some of its basics, followed by introduction of Session 1: Epidemiology and the Public Response
14:07 – Stephen discusses potential for integrating home healthcare visits into clinical trials
17:15 – Session 2: Clinical Aspects
17:52 – “NASH does come in different flavors.” Are we thinking about NASH with sufficient granularity?
20:32 – NASH pathogenesis and its link to other metabolic diseases
21:32 – Session 3: Deep dive into fibrosis
24:30 – Talk on “Innovations in imaging assessment in fibrosis” raises pivotal questions about advances we can make in cellular-level understanding
26:57 – Talk from Scott Friedman on “Common mechanisms, molecular evolution and resolution of fibrosis in NASH” yields several key ideas
28:45 – The importance of understanding stellate cell subtypes
33:37 – Jörn and Stephen select some key moments from Day Two
35:45 – Innovations in clinical trial bring researchers to consider competing risks and challenges in determining causes of mortality in NASH trials
40:26 – Session 8, “Global NASH,” describes the size and scale of the NASH challenge around the world
If you have questions or comments around the contents of this episode or the FDA workshop on NITs, drug development or any other themes addressed in this week, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!
